News | January 21, 2011

Xience Prime Granted European Approval to Treat Lower Leg Vessels

January 20, 2011 – European CE mark approval was granted to expand the indication of Abbott’s Xience Prime everolimus-eluting coronary stent for the treatment of critical limb ischemia (CLI) or severe claudication (pain) of the lower leg. CLI is the most advanced form of peripheral artery disease (PAD) that can ultimately lead to limb amputation.

The CE mark was supported by the data generated on the company's Xience V drug-eluting stent from the DESTINY trial. The 140-patient, investigator-sponsored, randomized, controlled, multicenter trial compared the Xience V to Abbott's Multi-Link Vision bare metal stent in patients with CLI of the lower leg. Patients with lesion lengths less than 40 mm were included in this trial.

The 12-month results from DESTINY demonstrated that Xience V had significantly better patency compared to the bare metal stent at 12 months (85.2 percent Xience V vs. 54.4 percent Multi-Link Vision; p=0.0001). This difference was especially pronounced between six and 12 months, where the difference in patency rate significantly diverged, as the rate for the bare metal stent fell to nearly 50 percent while the rate for Xience V remained above 85 percent. These results demonstrated that there is a significant benefit from an everolimus eluting stent versus a bare metal stent. The data from DESTINY were presented this week at the Leipzig Interventional Course (LINC) 2011, a medical congress held in Germany for physicians treating endovascular diseases.

"The DESTINY trial demonstrates that everolimus-eluting stents result in significantly better patency at 12 months compared to bare metal stents for patients with critical limb ischemia of the lower leg, and the use of everolimus eluting stents can potentially provide significantly better outcomes for these patients," said Marc Bosiers, M.D., head of the department of vascular surgery at St. Blasius Hospital in Dendermonde, Belgium, and principal investigator of the DESTINY trial. "A drug-eluting stent such as Xience Prime provides European physicians with another treatment option for patients with short lesions in the lower leg."

The Xience Prime is commercially available in CE mark countries. It has an improved stent design and a delivery system over the Xience V, offering greater flexibility and enhanced deliverability.

For more information:

Related Content

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS) bioabsorbable stent.

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS).

Feature | Stents Drug Eluting| January 17, 2018 | Dave Fornell
There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or b
Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting| December 13, 2017
Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration (FDA) approval of...
The Xience Sierra stent.
Technology | Stents Drug Eluting| November 09, 2017
November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience
Synergy Stent With Shorter DAPT Superior to Bare-Metal Stent in Elderly Patients
News | Stents Drug Eluting| November 06, 2017
November 6, 2017 — Elderly patients undergoing...
Biotronik Orsiro DES Shows Low Five-Year Event Rates
News | Stents Drug Eluting| November 03, 2017
November 3, 2017 — Biotronik's Orsiro...
Three-Month DAPT Non-Inferior for ACS Patients Treated With Combo Dual Therapy Stent

Image courtesy of OrbusNeich

News | Stents Drug Eluting| November 01, 2017
OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at the 29th annual...
News | Stents Drug Eluting| October 25, 2017
Elixir Medical Corp. announced it will unveil a new metallic drug-eluting stent (DES) platform at this year’s...
Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting| September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Overlay Init